Company news
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) news
Citius Pharmaceuticals, Inc. news releases on 6ix. Latest, Apr 13, 2022: Citius Pharmaceuticals Announces Key Management Realignment to Support…
Press releases — page 3
Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates
April 12, 2022
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission
April 5, 2022
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
February 14, 2022
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update
February 9, 2022
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update
December 14, 2021
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma
December 5, 2021
Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls
November 4, 2021
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
September 6, 2021
Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update
August 11, 2021
Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones
July 6, 2021
Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned
June 30, 2021
Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS
June 14, 2021
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
June 7, 2021
Citius Pharmaceuticals to be Added to Russell 2000® Index
June 6, 2021
Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting
May 24, 2021
Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations
May 16, 2021
Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update
May 12, 2021
Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
February 16, 2021
Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-Market
January 26, 2021
Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market
January 24, 2021
Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap
December 8, 2020
Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components
November 29, 2020
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)
October 6, 2020
Citius's Mino-Lok trial sites resupplied with registration batch product
September 29, 2020
Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial
September 28, 2020
Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®
September 21, 2020
Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance
September 14, 2020
Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap
August 25, 2020
Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
August 9, 2020
Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering
August 4, 2020
Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
August 3, 2020
Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19
July 21, 2020
Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President
July 13, 2020
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
July 12, 2020
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
June 25, 2020
Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy
June 1, 2020
Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®
May 25, 2020
Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May 17, 2020
Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May 13, 2020
Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 12, 2020
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19
April 26, 2020
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
March 31, 2020
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
March 25, 2020
Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
February 3, 2020
Citius Pharmaceuticals Issues Corporate Update
November 7, 2019
Citius Reaches First Interim Analysis Milestone for Mino-Lok® Pivotal Trial
October 6, 2019
Citius Announces Closing of $7.0 Million Underwritten Offering Priced At-the-Market
September 26, 2019
Citius Announces Pricing of $7.0 Million Underwritten Offering Priced At-the-Market
September 24, 2019
Citius Announces Change To Primary Endpoint In Mino-Lok® Phase 3 Study
September 3, 2019
Citius Announces $5.3 Million Registered Direct Offering Priced At-the-Market
March 31, 2019